Home / Business and Economy / Indian Pharma Outshines: FY26 Growth Stars Revealed
Indian Pharma Outshines: FY26 Growth Stars Revealed
30 May
Summary
- Pharma sector shows resilience, outperforming broader market.
- Five fastest-growing pharma companies identified for watchlist.
- Key growth drivers include Semaglutide, specialty products, and vaccines.
The Indian pharmaceutical sector has emerged as a standout performer on Dalal Street, exhibiting robust growth over the past year and outperforming the broader market indices. This resilience is attributed to strong sales growth among Indian generic exporters, who have successfully expanded their global footprint despite international market challenges.
Analysis has pinpointed five leading pharmaceutical companies demonstrating significant growth between FY23 and FY26. These companies, including OneSource Speciality Pharma, Rubicon Research, Viyash Scientific, AstraZeneca Pharma India, and Natco Pharma, are capitalizing on diverse product segments.
Key growth drivers for these companies include the successful launch and expansion of Semaglutide, a medication for diabetes and weight management, complex and specialty products in areas like pain management and CNS, and a booming veterinary medicine sector, particularly in Europe. AstraZeneca Pharma India also highlights strong contributions from its oncology and biopharmaceutical portfolios.
Despite market fluctuations and pricing pressures in certain segments, the outlook for these pharma companies remains optimistic. Future growth is expected to be sustained by ongoing product launches, expanding market access, and continued demand for innovative treatments across human and animal health sectors.
